BF Biosciences Limited (PSX:BFBIO)
Pakistan · Delayed Price · Currency is PKR 126.07
-2.58 (-2.01%)
At close: Oct 19, 2026
BF Biosciences Balance Sheet
Financials in millions PKR. Fiscal year is July - June.
Millions PKR. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 261.7 | 344.47 | 278.77 | 255.44 | 211.67 |
Short-Term Investments | - | - | - | 147.39 | 1,498 |
Trading Asset Securities | 311.07 | 1,167 | 39.01 | - | - |
Cash & Short-Term Investments | 572.77 | 1,511 | 317.78 | 402.83 | 1,710 |
Cash Growth | -62.10% | 375.55% | -21.11% | -76.44% | 34.58% |
Accounts Receivable | 349.48 | 184.24 | 204.61 | 93.81 | 52.71 |
Other Receivables | 45.87 | 45.51 | 49.33 | 49.64 | - |
Receivables | 395.35 | 229.75 | 253.94 | 143.45 | 67.93 |
Inventory | 3,052 | 1,740 | 893.81 | 852.24 | 406.55 |
Prepaid Expenses | 6.59 | 5.34 | 5.88 | 2.28 | - |
Other Current Assets | 418.63 | 349.88 | 205.26 | 190.5 | 110.93 |
Total Current Assets | 4,446 | 3,836 | 1,677 | 1,591 | 2,295 |
Property, Plant & Equipment | 4,632 | 4,306 | 4,175 | 4,070 | 2,135 |
Other Intangible Assets | 7.23 | 3.98 | 0.55 | 1.11 | - |
Other Long-Term Assets | 94.69 | 11.85 | 7.83 | 4.83 | 4.83 |
Total Assets | 9,180 | 8,159 | 5,860 | 5,667 | 4,435 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 288.42 | 321.12 | 269.06 | 225.38 | 394.28 |
Accrued Expenses | 910.77 | 541.51 | 266.09 | 144.7 | 13.82 |
Short-Term Debt | 225.9 | 29.36 | 328.7 | 473.39 | 149.35 |
Current Portion of Long-Term Debt | 342.07 | 328.05 | 292.72 | 356.88 | 57.65 |
Current Unearned Revenue | 144.6 | 134.26 | 150.87 | 135.59 | 99.86 |
Other Current Liabilities | 394.69 | 269.97 | 121.15 | 67.02 | - |
Total Current Liabilities | 2,306 | 1,624 | 1,429 | 1,403 | 714.96 |
Long-Term Debt | 1,046 | 1,367 | 1,591 | 1,772 | 1,537 |
Long-Term Unearned Revenue | 216.85 | 318.37 | 432.6 | 503.73 | 331.33 |
Long-Term Deferred Tax Liabilities | 316.99 | 186.58 | 48.31 | 13.51 | 26.55 |
Total Liabilities | 3,886 | 3,497 | 3,500 | 3,693 | 2,610 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 265 | 265 | 190 | 190 | 190 |
Additional Paid-In Capital | 1,780 | 1,780 | - | - | - |
Retained Earnings | 3,249 | 2,617 | 2,170 | 1,784 | 1,502 |
Comprehensive Income & Other | - | - | - | - | 132.7 |
Shareholders' Equity | 5,294 | 4,662 | 2,360 | 1,974 | 1,825 |
Total Liabilities & Equity | 9,180 | 8,159 | 5,860 | 5,667 | 4,435 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Total Debt | 1,614 | 1,725 | 2,212 | 2,603 | 1,744 |
Net Cash (Debt) | -1,041 | -213.54 | -1,894 | -2,200 | -34.26 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -11.78 | -2.64 | -29.91 | -34.74 | -0.54 |
Filing Date Shares Outstanding | 88.33 | 88.33 | 63.33 | 63.33 | 63.33 |
Total Common Shares Outstanding | 88.33 | 88.33 | 63.33 | 63.33 | 63.33 |
Working Capital | 2,139 | 2,212 | 248.08 | 188.34 | 1,580 |
Book Value Per Share | 59.93 | 52.78 | 37.26 | 31.17 | 28.82 |
Tangible Book Value | 5,287 | 4,658 | 2,359 | 1,973 | 1,825 |
Tangible Book Value Per Share | 59.85 | 52.73 | 37.25 | 31.15 | 28.82 |
Land | 25.36 | 25.36 | 25.36 | 25.36 | - |
Buildings | 993.57 | 993.57 | 236.06 | 214.16 | - |
Machinery | 4,318 | 4,131 | 1,191 | 708.94 | - |
Construction In Progress | 538.38 | 133.03 | 3,516 | 3,884 | - |